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Abstract
Parkinson’s disease (PD) is a common neurodegenerative disease characterized by the loss of dopaminergic neurons in the
substantia nigra and the aggregation of a-synuclein into Lewy bodies. Existing therapies address motor dysfunction but do
not halt progression of the disease. A still unresolved question is the biochemical pathway that modulates the outcome of
protein misfolding and aggregation processes in PD. The molecular chaperone network plays an important defensive role
against cellular protein misfolding and has been identified as protective in experimental models of protein misfolding
diseases like PD. Molecular mechanisms underlying chaperone-neuroprotection are actively under investigation. Current
evidence implicates a number of molecular chaperones in PD including Hsp25, Hsp70 and Hsp90, however their precise
involvement in the neurodegenerative cascade is unresolved. The J protein family (DnaJ or Hsp40 protein family) has long
been known to be important in protein conformational processes. We assessed sensory and motor function of control and
PD rats and then evaluated the brain region-specific expression levels of select J proteins by Western analysis. Surprisingly,
we observed a widespread 26 kDa breakdown product of the J protein, TID1, (tumorous imaginal discs, mtHsp40 or DnaJ3)
in a 6-hydroxydopamine (6-OHDA) rat model of PD in which food handling, gait symmetry and sensory performance were
impaired. Greater behavioral deficits were associated with lower TID1 expression. Furthermore, direct application of either 6-
OHDA or MPP
+ (1-methyl-4-phenylpyridinum) to CAD (CNS-derived catecholinaminergic neuronal cell line) cell cultures,
reduced TID1 expression levels. Our results suggest that changes in cellular TID1 are a factor in the pathogenesis of PD by
impeding functional and structural compensation and exaggerating neurodegenerative processes. In contrast, no changes
were observed in CSPa, Hsp40, Hsp70, Hsc70 and PrP
C levels and no activation of caspase3 was observed. This study links
TID1 to PD and provides a new target for therapeutics that halts the PD progression.
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Introduction
Parkinson’s disease (PD), a neurodegenerative disease that afflicts
1% of the population over 65, is characterized by degeneration of
dopaminergic neurons in the substantia nigra and formation of
intracytoplasmic -synuclein aggregates called Lewy bodies [1].
Mutationsina-synuclein,DJ-1,PINK-1andParkin aswellastoxins
like 6-hydroxydopamine (6-OHDA), rotenone, paraquat and 1-
methyl-4-phenyl 1,2,3,6 tetrahyrdopyridine (MPTP) lead to par-
kinsonism/PD suggesting that degeneration involves a complex and
multifaceted pathway [2,3]. Clinical symptoms of PD include
rigidity, bradykinesia, resting tremor and postural instability. As the
disease progresses, patients may also develop serious cognitive
decline, which is thought to be causally linked to Lewy body
pathology [4]. There is no known cure to prevent or reverse the
progression of PD. In this study we begin to address molecular
changes underlying PD by evaluating expression levels of putative
neuroprotective proteins in PD rats rigorously evaluated for
sensorimotor behavior.
Although evidence has suggested a key role of a-synuclein
aggregation in the pathology of PD, its exact role is still under
debate [5]. Downstream of a-synuclein misfolding the pathogenic
sequence of events have been difficult to construe, but studies have
shown that abnormal a-synuclein aggregation is linked to altered
lipid metabolism that leads to mitochondrial dysfunction in
dopaminergic neurons [6,7]. Dysfunction of an early-acting
chaperone in the pathogenic sequence of events could possibly
have a toxicity-initiating role while reduced levels and activities of
late-acting molecular chaperones in the pathogenic sequence may
undermineprotectionandrecoveryfromcellulardamageassociated
with protein misfolding. While enhancement of molecular chaper-
one expression has been reported to protect against a-synuclein
toxicity [8], many questions remain regarding the role of
chaperones in PD progression. One family of co-chaperones known
PLoS ONE | www.plosone.org 1 October 2011 | Volume 6 | Issue 10 | e26045as J proteins are an evolutionarily conserved family (aka DnaJ/
Hsp40 family), each member containing a 70 amino acid
tetrahelical J domain required for stimulating the ATPase activity
of Hsc70 (heat shock cognate protein of 70 kDa) [9]. J proteins
adapt Hsc70 for specialized folding tasks and seem to possess
decisional power on whether to direct client proteins toward
maturation/refolding or degradation. Malfunction of J proteins
may therefore be pivotal in the failure of protein homeostasis and
neurodegeneration observed in PD.
We tested elements of this hypothesis by evaluating expression
levels of select J proteins in a rat model of neuronal death by
nigrostriatal injection of 6-OHDA. 6-OHDA exposure was chosen
as a PD mimetic in our study because the 6-OHDA model has
been extensively characterized functionally [10]. The 6-OHDA-
lesion can be compared to other PD mimetics, involves changes in
gene transcription [11], and is exaggerated by stress [12]. We
identified a 26 kDa immunoreactive product of TID1, a 40/
43 kDa J protein in the rat model of PD suggesting that TID1-
mediated stability and folding is compromised in PD.
TID1, the mammalian homologue of the Drosophila tumor
suppressor Tid56, is proposed to have a role in multiple signal
transduction processes including clustering of acetylcholine recep-
tors at the neuromuscular junction [13] nerve growth factor-
induced neurite outgrowth [14], apoptosis [15], and mitochondrial
translocation of proteins [16]. TID1 was first identified as a viral
interacting protein [17]. While TID1 knockout mice are embryonic
lethal [18], mutations in TID1 have been identified in glioma cell
lines [15], indicative of an involvement of TID1 in cell survival
pathways. Mammals express two alternatively spliced forms of
TID1: TID1-long (43 kDa) and TID1-short (40 kDa). Both
isoforms have an amino-terminal mitochondrial targeting sequence,
a J domain, a glycine/phenylalanine linker region, a central
cysteine-rich region resembling a zinc finger repeat and a carboxy
terminal region with some similarity to DnaJA1/DnaJA2. J
domains are comprised of four a helices with a highly conserved
tripeptide of histidine, proline and aspartic acid located between
helices II and III and are found in all members of the J protein
family. Via their J domains, J proteins interact with and activate the
Hsp70/Hsc70 family of chaperones, which is thought to have a
substantive role in PD pathology [19–23]. TID1 localizes to
mitochondriaas well as cytosolsupporting the hypothesis that TID1
is important for protein import to the mitochondria [16,24].
The Hsp70/Hsc70 family has a critical function in a range of
cellular processes including the folding of newly synthesized
proteins and the rescue of misfolded proteins [25,26]. Hsp70
colocalizes with Lewy bodies [23]. In PD fly models [19] and in
neuroglioma cells [20], overexpression of Hsp70 has been shown
to reduce a-synuclein toxicity. In particular, Hsp70 inhibits a-
synuclein fibril assembly [21], and reduces a-synuclein aggregates
in vivo [27]. Inhibition of Hsp70 by BAG5, a BAG domain-
containing protein, is reported to lead to dopaminergic neuron
death in an in vivo model of PD disease [28]. In contrast, it has
been reported that Hsp27 but not Hsp70 has a protective effect on
a-synuclein-induced toxicity in a rat model of Parkinson disease
[29]. In addition, when human a-synuclein containing a point-
mutation and Hsp70 are co-overexpressed, Hsp70 was not
observed to have a beneficial effect on behavior and a-synuclein
aggregation in vivo [30]. Conformational work by the Hsp70/
Hsc70 family is subject to a multitude of regulators [9,25], and
incompatible findings regarding the role of Hsc70/Hsp70 in PD
may well be due to such regulatory cofactors, however further
investigation is required.
It has remained untested if members of the J protein family
have a substantive role in PD. In order to begin to understand the
role that J proteins have in PD we have evaluated the levels of
select J proteins in a 6-OHDA rat model of PD. Rats received a
unilateral 6-OHDA lesion of the nigrostriatal bundle and were
tested in a behavioral test battery comprising a new scoring
system for skilled forelimb use, gait symmetry and somatosensory
function. 27–33 days following 6-OHDA exposure we observed
lower molecular weight (26 kDa) immunoreactive degradation
products of the J protein TID1 implicating changes in TID1
activity in degeneration associated with PD. This change was
specific to the J protein TID1 in that neither the stress-induced J
protein, Hsp40 (heat shock protein of 40 kDa), nor the anti-
neurodegenerative J protein, CSPa (cysteine string protein),
expression levels were altered in PD rats. The 26 kDa TID1
entity was observed outside the site of 6-OHDA application. It
has been generally accepted that TID1 is involved in tumor
suppressor activities and loss of TID1 promotes carcinogenesis,
here we link TID1 to PD. We speculate that the widespread,
bilateral alterations of TID1 would impair cellular ability to
maintain mitochondrial protein homeostasis and TID1-specific
signaling pathways.
Results and Discussion
PD 6-OHDA lesion rats show severe sensorimotor deficits
To begin to address the hypothesis that depletion of neural
chaperones contributes to PD pathology, we have examined the
levels of the J proteins TID1, CSPa and Hsp40 in the 6-OHDA
rat model of PD. Administration of 6-OHDA, a toxic metabolite
of dopamine found in the brain and urine of PD patients, is known
to produce selective destruction of catecholaminergic neurons.
Behavioral tests were performed at 21–26 days following left
nigrostriatal 6-OHDA infusion, a time at which maximum
dopamine depletion can be expected. Behavioral tests assessed
various aspects of sensorimotor function in order to complement
the comprehensive molecular assessment. In all tests, rats
demonstrated significant deficits in motor and somatosensory
function (Figure 1). Specifically, while control rats reliably
responded to the tactile stimulation (mean score 0.63+/20.52), 6-
OHDA lesion rats were rarely responsive to stimulation (2.56+/
20.63 t=7.51, p,0.0001; Figure 1A). These findings indicate
severe somatosensory deficits in 6-OHDA lesion animals.
Furthermore, 6-OHDA lesion rats showed significant gait
asymmetry (Figure 1B). While controls did not show spontane-
ous preference when turning (mean score 0.25+/20.46), 6-OHDA
lesion animals (2.94+/20.25) without exception showed a bias
towards the ipsilateral-to-lesion side when turning (t=218.65,
p,0.001). These scores indicate that 6-OHDA lesion rats showed
severe motor asymmetry in their stepping pattern leading to
ipsilesional turns.
Skilled movement in 6-OHDA lesion rats was also tested and
revealed significant differences to control animals (Figure 1C).
Lesion rats displayed significant impairment in handling and
eating pieces of uncooked pasta. Compared to controls (mean
score 0.5+/20.76), 6-OHDA lesion animals (2.31+/20.95) on
average needed four times longer to consume a single piece of
spaghetti (t=4.7, p,0.0001). The time measurement indicates
difficulty in distal limb and digit use when handling the pasta in
addition to orofacial impairments while chewing.
The behavioral findings in 6-OHDA rats mimic the motor and
sensory deficits typically displayed in human PD. After behavioral
testing was completed the striatum, midbrain, cortex, prefrontal
cortex, cerebellum and hippocampus were dissected from right
and left hemispheres 27–33 days following injection, solubilized
and subjected to Western analysis.
The Mitochondrial J Protein TID1 and PD
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26 kDa TID1 immunoreactive species
An abundant bilateral 26 kDa immunoreactive product of the J
protein, TID1 was observed in the midbrain of 6-OHDA but not
control rats (LH midbrain 3.2 fold increase n=6) (Figure 2).I n
contrast, the 43 kDa TID1long (TID1L) and 40 kDa TID1short
(TID1S) isoforms were clearly observed in midbrain isolated from
the right and left hemisphere of both the saline and 6-OHDA
treated animals. Both apoptotic and anti-apopotic activities have
been reported for TID1. Specifically, overexpression of TID1L is
Figure 1. The performance of rats is influenced by 6-OHDA-
lesions. (A) Sensory Impairment test, (B) Gait Symmetry Impairment
test (C) Food Handling Impairment test in 6-OHDA lesion and saline
control rats. Following left hemisphere injection of 2 ml of 6-OHDA or
saline, rats were tested for behavioral deficits. A higher behavioral score
indicates greater behavioral deficit. *** indicates significance p,0.001.
doi:10.1371/journal.pone.0026045.g001
Figure 2. Unilateral 6-OHDA-lesions increased TID1 (DnaJA3)
chaperone breakdown. (A) Following left hemisphere injection of
2 ml of 4 mg/ml 6-OHDA or saline, rats were tested for neurodegen-
eration and the indicated brain region were dissected 27–33 days
following injection. 30 mg of solubilized midbrain was heated at 95uC
for 5 min, resolved by SDS-PAGE, transferred to nitrocellulose and
probed with anti-TID1 monoclonal antibody. The Western blot shown is
representative of 11 6-OHDA/saline pairs of rats. Actin is shown as a
loading control. (B) Midbrain samples were fractionated into soluble
and insoluble and subjected to Western analysis. (C) TID1 expression in
the indicated regions of saline injected rats was evaluated by Western
analysis with anti-TID1 monoclonal antibody and quantitated by
Quantity One (BioRad). (D) TID1 expression in 30 mg of solubilized
hippocampus. The Western blot shown is representative of 11 6-OHDA/
saline pairs of rats. Actin is shown as a loading control.
doi:10.1371/journal.pone.0026045.g002
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while TID1S over expression is observed to reduce apoptosis by
these agents [31]. It is interesting that a 38 kDa TID1 splice
variant with limited expression has been described [32,33] and
found to be highly expressed in two leukemia cell lines [34].
The 26 kDa immunoreactive product is most likely a
breakdown product of one of the splice variants of TID1. Since
we did not detect the 38 kDa TID1 splice variant in any brain
regions evaluated from either control or 6-OHDA rats, we predict
that the 26 kDa TID1 derives from the 43/40 kDa TID1 variants.
Despite the increase in the 26 kDa immunoreactive band, no
reduction in midbrain expression levels of either TID1L or TID1S
was observed and no change in the ratio of the two isoforms
TID1L and TID1S were detectable indicating that TID1 levels are
maintained in the PD model. Actin is shown as a loading control.
Even though TID1 has an N terminal mitochondrial targeting
sequence, it is known to localize to both the mitochondria as well
as transiently in the cytosol [24] relatively less is known about the
cellular role of the cytosol to mitochondria transition of TID1.
Therefore, we fractionated (30 min 21,000Xg) midbrain lysates to
establish if the 26 kDa TID1 co fractionated with TID1L,-S
(Figure 2B). TID1L,-S was found in the insoluble (1% TX100,
0.1%SDS) fraction while the 26 kDa product was present in the
soluble fraction. Although the monoclonal antibody utilized was
generated against full-length human TID1 and the epitope of the
antibody is not reported, the antibody does not distinguish
between 40/43 kDa TID1 indicating the antibody does not target
the C terminal 27 amino acid region unique to the 43 kDa variant
of TID1. We speculate that increases in mitochondrial perme-
ability and/or reduction in translocation of TID1 to the
mitochondria may well lead to generation of soluble 26 kDa
TID1. In fact, 6-OHDA has been shown to increase mitochon-
drial permeability [35] and the cytosolic residency time and half
life of TID1 has been proposed to be influenced by interactions
with cytosolic proteins [24] supporting these ideas.
Figure 2C demonstrates that in control rats TID1 is widely
expressed in striatum, midbrain, cortex, prefrontal cortex,
cerebellum and hippocampus. A darker exposure (bottom panel)
shows that the 26 kDa immunoreactive TID1 product is weakly
detectable in striatum, midbrain, cortex, prefrontal cortex,
cerebellum and hippocampus of control rats with the strongest
immunoreactivity found in the hippocampus. Figure 2D shows
the 26 kDa TID1 breakdown product is observed in the
hippocampus of both saline as well as 6-OHDA-treated rats, but
3–4 fold higher in 6-OHDA-treated rats. Actin is shown as a
loading control. Figure 3 clearly shows that TID1 expression is
Figure 3. TID1 is widely expressed in brains of 6-OHDA-lesioned rats. TID1 was widely detected by immunohistochemistry in frozen rat
brain serial sections. (A) Hippocampus: non-lesion hemisphere. (B) Hippocampus: lesion hemisphere. (C) Substantia nigra: non-lesion hemisphere. (D)
Substantia nigra: lesion hemisphere. (E) Striatum: non-lesion hemisphere. (F) Striatum: lesion hemisphere. Scale: 100 mm.
doi:10.1371/journal.pone.0026045.g003
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6OHDA lesion and non lesion hemisphere of PD rats consistent
with western analysis.
In response to a range of stressful stimuli including hyperther-
mia, a conserved cellular program called the heat shock response is
activated and the expression of several chaperones is induced that
enhances cell survival. Therefore we next evaluated fractions from
control and 6-OHDA rats for the possible induction of stress
induced chaperones. Figure 4A shows that no differences were
observed in expression of either Hsp70 or Hsp40 in the striatum of
6-OHDA compared to control rats. Actin is shown as a loading
control. Hsp70 expression was not observed in any brain region of
either PD or control rats, (Figure 4A & B, and data not
shown). Furthermore, the constitutively expressed isoform,
Hsc70, is abundantly expressed in striatum and its expression
does not change in 6-OHDA rats. Hsp40 is endogenously
expressed and no further elevation in Hsp40 levels is observed in
6-OHDA animals. Like the striatum, no change in Hsp70, Hsp40
and Hsc70 were identified in any brain regions examined (data not
shown).
Taken together these data identify a widespread cytosolic
26 kDa breakdown product of the constitutively expressed J
protein, TID1, in the rat neurotoxin model of PD and suggest that
TID1 may be involved in altered mitochondrial dynamics in PD
progression. In contrast, we found no difference in the expression
of the protective heat shock chaperones, Hsp70 and Hsp40,
indicating that the critical neuroprotective stress-induced chaper-
ones are not induced in PD 27–33 days after onset. Moreover, no
difference in expression levels of the constitutive chaperone Hsc70
between 6-OHDA and control rats was found, indicating the
Hsc70 chaperone reservoir is not depleted. Our identification of
the breakdown products of the mitochondrial localized J protein
TID1 but not the stress-induced J protein Hsp40, is consistent with
the recognition of a critical role for mitochondria in inherited
forms as well as neurotoxin-induced forms of PD.
Unilateral 6-OHDA-lesions increases a-synuclein
expression but does not alter CSPa expression
Next we determined levels of a-synuclein in the PD rat model.
The exact function of a-synuclein, a cytosolic neuronal protein
that localizes with synaptic vesicles as well as the nucleus [36] is
not established, however its misfolding is a critical determinant in
PD [1]. a-synuclein levels correlate with synaptic function [37]. In
midbrain of either 6-OHDA or control treated rats, a-synuclein
located to the soluble fraction (Figure 5A). Figure 5B shows that
while a-synuclein expression is higher in the striatum of 6-OHDA
rats it is not altered in other brain regions (5B right panel & data
not shown). Interestingly, a-synuclein exerts a neuroprotective
action by preventing neurodegeneration caused by deletion of the
presynaptic J protein cysteine string protein (CSPa) [38]. CSPa is
a synaptic vesicle anchored J protein with neuroprotective
properties [39,40]. Therefore, we next examined the possibility
that CSPa levels were reduced in brain regions of 6-OHDA
compared to saline treated rats. The expression level of CSPa was
not altered in 6-OHDA rats. CSPa forms dimers, a process that is
modified by heat shock [41] as well as the flavonoid quercetin
[42], no differences in CSPa dimerization were found between
control and PD rats. Figure 5C shows that CSPa levels are high
in all brain regions examined with lowest expression in the
cerebellum and that a-synuclein levels are also low in cerebellum.
While CSPa-knockout mice show approximately 50% decrease in
SNAP25 (synaptosomal-associated protein of 25 kDa) levels, a
core component of the secretory machinery [38,43], CSPa and
SNAP25 were not altered in the toxin triggered PD rats
(Figure 5C&D) suggesting that the mechanism(s) of degeneration
in CSPa null mice and PD rats are distinct. Actin is shown as a
control. Taken together, in PD rats there are widespread, bilateral
changes in the J protein TID1 and a localized increase in a-
synuclein. No change in the levels of the neuroprotective J proteins
CSPa or Hsp40 or the downstream SNAP25 target was observed
in PD rats.
Cellular prion protein levels do not change in a rat model
of PD
Several studies have suggested a protective function for cellular
prion protein (PrP
C) [44–47,47–56] and it follows that changes in
PrP
C expression might influence progression of PD. Nonetheless,
deletion of PrP
C was not found to alter the disease phenotype in
the a-synuclein transgenic mouse model of PD [57]. We therefore
assessed PrP
C levels in brain regions of the 6-OHDA rat model.
Figure 6A shows that no detectable changes in PrP
C levels were
found in striatum and hippocampus in 6-OHDA compared to
control rats. No differences were observed in other regions (data
not shown). In the control rats, PrP
C is widely expressed with
lower levels in the midbrain and cerebellum (Figure 6B and C).
Figure 4. Unilateral 6-OHDA-lesions do not induce the heat
shock chaperones Hsp70 and Hsp40. (A) Following left hemi-
sphere injection of 2 ml of 4 mg/ml 6-OHDA or saline, rats were tested
for neurodegeneration and the expression level of Hsc70, Hsp70 and
Hsp40 in the striatum of saline (control) or 6-OHDA lesion rats was
determined by Western analysis. (B) Western blot showing expression
of the indicated chaperones in the striatum (STR), midbrain (MB), cortex
(CTX), prefrontal cortex (PFC), cerebellum (CB) and hippocampus (HPC)
of saline injected rats were evaluated with indicated antibodies and
quantified by Quantity One (BioRad).
doi:10.1371/journal.pone.0026045.g004
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found in expressed levels of the neuroprotective J protein, CSPa,
the heat shock proteins or cellular prion protein in the rat
neurotoxin model of PD. Although, these results are mainly
negative we report them because they address the critical question
of the role that these proteins have in PD progression.
6-OHDA and MPP
+ reduce TID1 expression in CAD cells
Since the widespread increase in levels of the 26 kDa TID1 at
27–33 days following 6-OHDA may reflect either neurotoxicity or
compensatory changes in the PD rat model, we therefore
evaluated TID1 levels in CAD (CNS-derived catecholinaminergic
neuronal cell line) cells acutely treated with the neurotoxins 6-
OHDA and MPP
+ (1-methyl-4-phenylpyridinium). Figure 7A
demonstrates that 64 mM 6-OHDA selectively reduced TID1L,-S
expression in CAD cells. Furthermore, 16 mM MPP
+, a mito-
chondrial complex I inhibitor that compromises mitochondrial
integrity and causes Parkinsonism in primates, also reduced
TID1L,-S expression in CAD cells and did not induce heat shock
chaperones (Figure 7B). The 26 kDa TID1 product was not
observed in either control or toxin-treated neuroblastoma cells.
Like that found in intact animals, heat shock chaperones were not
induced following neurotoxin treatment. When CAD neuroblas-
toma cells and Eahy endothelial cells were provided with a
conditioning heat shock (40 min at 42uC), Hsp70 was induced
while TID1 remained unchanged (Figure 7C), confirming TID1
and the TID1 26 kDa product is not a component of the heat
shock response. Eahy cells constitutively express Hsp70 which is
upregulated in response to heat shock. Our results show that levels
of TID1 are acutely susceptible to 6-OHDA and MPP
+ treatment.
In response to either 6-OHDA or MPP
+ a reduction in TID1L,-S
levels is observed in cultured cells while in vivo localized 6-OHDA
treatment initiates a bilateral, widespread 26 kDa TID1 product.
While direct application of 6-OHDA to cultured cells triggered
acute loss of cellular TID1, in contrast in vivo application to axons
in the nigrostriatal bundle triggered widespread appearance of the
Figure 5. PD rats show increased levels of a-synuclein but not
CSPa. Following left hemisphere injection of 2 ml of 4 mg/ml 6-OHDA,
rats were tested for neurodegeneration and were dissected 27–33 days
following injection. (A) 100 mg of total midbrain was fractionated,
resolved by SDS-PAGE, transferred to nitrocellulose and a-synuclein was
evaluated by Western blot. (B) a-synuclein, CSPa and SNAP25
expression levels of saline (control) or 6-OHDA lesion rats in the
midbrain and striatum were evaluated by Western analysis using the
monoclonal anti-a-synuclein antibody, the monoclonal anti-a-SNAP25
antibody or the anti-CSPa polyclonal antibody. (C) Western analysis of
a-synuclein, CSPb and SNAP25 for striatum, midbrain, cortex, prefrontal
cortex, cerebellum and hippocampus of the left hemisphere of saline
induced rats. Actin is shown as a loading control.
doi:10.1371/journal.pone.0026045.g005
Figure 6. Cellular prion protein (PrP
C) does not change in PD
rats. Following left hemisphere injection of 6-OHDA, rats were
dissected 27–33 days post-lesion and 30 mg of homogenate isolated
from the indicated brain regions was evaluated by Western analysis
with the monoclonal antibody 6H4 (Prionics). (A) PrP
C expression in
right and left striatum and hippocampus of saline and 6-OHDA lesion
rats. (B) Western analysis of PrP
C in the striatum (STR), midbrain (MB),
cortex (CTX), prefrontal cortex (PFC), cerebellum (CB) and hippocampus
(HPC) of the left hemisphere of saline induced animals. (C) Quantifi-
cation via Quantity One (BioRad) of the Western analysis. The
quantification was carried out for eight individual saline treated rats.
doi:10.1371/journal.pone.0026045.g006
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mechanisms may be involved. The differences observed between
PD rats and neuroblastoma cell lines are under continuing
investigation, that said, toxin-induced TID1 changes are clear in
both experimental models.
During the course of these experiments we discovered that the
levels of the 26 kDa TID1 fragment were variable between PD
rats. For example, Rat #7 displayed smaller behavioral impair-
ments associated with higher presence of TID1 fragment in the
striatum, midbrain and hippocampus. By contrast, rat #16
showed greater behavioral impairments associated with lower
presence of TID1 in any of the regions. Figure 8 (top panel)
shows the 26 kDa TID1 fragment in the striatum, midbrain and
hippocampus of 8 separate 6-OHDA rats. The 26 kDa TID1
fragment was more abundant in some rats. Since TID1 is
implicated in multiple signaling pathways (e.g. cell proliferation,
and apoptosis) and over expression of TID1 has been shown to
enhance ERK/MAP kinase activation [14], we evaluated the
phosphorylated ERK levels in the 6-OHDA rats, to establish if the
26 kDa fragment correlated with increased ERK activation. Many
6-OHDA rats showed increased levels of phosphoERK and this
increase in phosphorylation did not correlate with changes in total
ERK levels (Figure 8). The 6-OHDA rats with the highest levels
of the 26 kDa fragment did not show the greatest ERK activation.
The lower panel shows that there is no activation of caspase 3 in
any animals. These data lead us to conclude that in 6-OHDA rats,
both the 26 kDa TID1 product and activation of the ERK/MAP-
Kinase pathway correlate with dopamine depletion, however
cellular levels of the 26 kDa TID1 product do not correlate with
levels of ERK phosphorylation at the 27–33 day time point.
Next we evaluated phosphorylated ERK and total ERK levels
in 6-OHDA treated CAD cells (Figure 9; top panel is from 7A for
reference). 6-OHDA-treatment, increased ERK phosphorylation
in a dose dependent manner while no change was observed in total
ERK expression. This small increase in ERK phosphorylation is
not linked to the presence of the 26 kDa TID1 fragment which is
not found in toxin-treated neuroblastoma cells. No activation of
caspase 3 was detectable following 24 hour 6-OHDA treatment of
CAD cells.
In conclusion, members of the J protein family have been
proposed to direct client proteins either to maturation or
degradation and therefore may be pivotal in controlling the
delicate cellular protein folding balance. We speculate that the
TID1 quality control system is compromised in PD. Specifically
that the 26 kDa TID1 breakdown product plays a role in the
pathology of toxin induced Parkinson disease. Widespread
presence of the 26 kDa/TID1 entity is documented in the absence
of activation of the apoptotic marker caspase 3, corroborating the
idea that a specific cellular change outside of the initial site of 6-
OHDA application promotes neurotoxicity. Since specific groups
of neurons are vulnerable to death in PD, further experimentation
is required to address the time frame of cellular TID1 changes in
PD, whether cellular TID1 undergoes changes in other experi-
mental models of PD as well as other models of neurodegener-
ation. The observations reported here are compatible with the
notion that strategies to prevent or ameliorate cellular damage in
neurodegenerative diseases would ideally target cellular chaper-




+ were from Sigma Aldrich. Anti CSPa
polyclonal antibody was prepared as described previously [58].
Anti-Hsp70 mouse monoclonal and anti-Hsp40 rabbit polyclonal
were from Assay Design. Anti-Hsc70/Hsp70 mouse monoclonal,
anti-b-actin mouse monoclonal and protease inhibitor were from
Sigma. 6H4 anti-prion mouse monoclonal was from Prionics, anti-
a-synuclein mouse monoclonal was from BD Bioscience, anti-Tid1
mouse monoclonal was from Thermo Scientific Fisher or from
Abcam.
Statement on Animal Welfare
Adult female Long-Evans hooded rats (300–350 g) were raised
at the University of Lethbridge vivarium and housed in groups of
two in standard polycarbonate shoebox cages. The housing room
was maintained on a 12:12 light/dark cycle, with lights on at 7:30
am. The temperature was kept at 22uC and relative humidity at
30%. All procedures were performed according to standards set by
the Canadian Council of Animal Care and approved by the
Figure 7. 6-OHDA and MPP
+ reduce TID1 levels in CAD cells.
Western analysis of TID1 following (A) 6-OHDA or (B) MPP
+ treatment
for 24 hrs of CAD cells or Eahy cells. Expression levels of TID1, Hsp40
and Hsp70 were detected using the indicated antibodies. Actin staining
is shown as a loading control (C) Western analysis of TID1 levels in CAD
and Eahy929 control cells following Heat shock treatment (HS).
doi:10.1371/journal.pone.0026045.g007
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1008). A total of 24 rats were used in this study.
Nigrostriatal 6-OHDA Lesions. All animals received a
unilateral 6-OHDA lesion of the nigrostriatal bundle in the left
hemisphere [59]. Thirty minutes prior to surgery, rats received
desmethylimipramine (25 mg/kg i.p.; Sigma-Aldrich). The rats
were then anesthetized using isoflurane (4% for initiation, 1.5% for
maintenance, mixed with oxygen). Neurotoxic lesions of the
nigrostriatal bundle were induced by infusing 2 ml of 4 mg/ml
(16 mM) 6-OHDA hydrobromide, i.e., in total 30 nmol 6-OHDA,
(in 0.02% saline ascorbic acid solution; [12]) at the following
coordinates: 4.0 mm posterior to bregma, 1.5 mm lateral to the
midline, and 8.5 mm ventral to the skull surface with skull flat
between lambda and bregma [60]. Infusion took place over five
minutes, with five minutes for diffusion. The skin was then sutured
and cleaned, and the animals were allowed to recover on a heating
pad before they were returned to their home cage.
Sensorimotor Behaviour
Food Handling Analysis. Abnormalities of posture, limb
and mouth movements after 6-OHDA lesion can be observed
when rats eat small pieces of uncooked pasta [61,62]. The motor
disability is reflected in the time to eat a piece of pasta. Rats were
provided with one 5 cm piece of spaghetti. The time required to
eat a piece of spaghetti was recorded, starting with the first contact
of the snout with the pasta until the entire piece was consumed and
both paws returned to the ground. The following rating scale was
used to score the ability to handle and eat the pasta: 0 points were
given if the eating time was less than 60 s; 1 point was given if the
eating time ranged between 60 and 90 s; 2 points were given if the
eating time ranged between 90 s and 120 s; 3 points were given if
the eating time exceeded 120 s. This test was repeated three times,
separated by a 5 min break each, and averages were calculated.
Gait Symmetry Analysis. Gait symmetry and spontaneous
turning preference was examined as a predictor of neostriatal
Figure 8. 6-OHDA treatment causes ERK phosphorylation and does not activate the Caspase pathway. 27–33 days following left
hemisphere injection of 6-OHDA, brain regions were dissected. 30 mg of homogenate isolated form the striatum (STR), midbrain (MB) and
hippocampus (HPC) were heated at 95uC for 5 min., resolved by SDS-PAGE, transferred to nitrocellulose membrane and probed for TID1,
phosphorylated ERK (phosphorylated p44/42 MAPK), total ERK expression (total p44/42 MAPK) and caspase 3. Lanes from left to right are: control (rat
18), 6-OHDA rats 1, 2, 3, 6, 7, 12, 13, and 16.
doi:10.1371/journal.pone.0026045.g008
Figure 9. Effect of 6-OHDA treatment for 24 hrs on CAD cells.
40 mg of cell lysate was resolved by SDS-PAGE, transferred to
nitrocellulose membrane and stained for TID1, phosphorylated ERK,
total ERK, caspase 3 and actin as loading control.
doi:10.1371/journal.pone.0026045.g009
The Mitochondrial J Protein TID1 and PD
PLoS ONE | www.plosone.org 8 October 2011 | Volume 6 | Issue 10 | e26045dopamine depletion [10,63]. Following habituation, rats were
allowed to explore on an open table top. The ratio of ipsilateral
versus contralateral turns was scored using the following rating
scale: 0 points if a rat did not show a preference for either side (50/
50); 1 point if a rat showed an occasional preference for the
ipsilateral-to-lesion side (i.e. 60/40, 70/30); 2 points if a rat
showed a frequent preference for the ipsilateral side (i.e. 80/20,
90/10); 3 points if a rat showed absolute preference for ipsilateral
side (i.e. 100/0) or the rat was not locomotive and did not turn.
The lateral bias of animals was scored for the first ten turns after
being placed on the table top. The average was calculated for
further analysis.
Tactile Stimulation Analysis. Rats with unilateral 6-
OHDA lesion show a biased response to tactile stimulation [64].
Following habituation to a tabletop, the rat’s vibrissae were
stimulated using a Q-tip. The testing side was alternated until 5
trials per side were completed. A score for the affected side was
determined according to the following rating scale. 0 points were
given if the rat responded to all five contacts; 1 point was given if
the rat responded to three or four contacts; 2 points were given if
the rat responded to one or two contacts; 3 points were given if the
rat does not respond to any contact. The test was repeated twice
and average scores were calculated.
Statistical Analysis. Statistical analysis was performed using
Statview software package 5 for Macintosh (Abacus Concepts
Inc.). The results were subject to analysis of variance (ANOVA) for
repeated measurements followed by unpaired Student’s t-tests for
comparisons of means and variances between groups. In all
statistical analyses, a p-value of less than or equal to 0.05 was
considered significant. All data are presented as mean +/2
standard error of the mean (SEM).
Immunohistochemistry. TID1 was widely detected by
immunohistochemistry in frozen PD rat brains. Serial coronal
brain sections from the striatum, hippocampus, and substantia
nigra were analyzed. Detection of TID1 immuno-reactive cells
was enhanced by treating the sections with 50 mM Tris-HCl
buffer, pH 9.5, in a microwave oven for 20 min, modified from
procedures described elsewhere [65,66]. Brain sections were
incubated overnight in primary antibody mouse monoclonal
[RS13] to TID1 (Abcam). Controls were performed omitting the
primary antibody. Sections were incubated with a secondary anti-
mouse biotinylated antibody (Vector), which was detected using
the Elite ABC-peroxidase kit (Vectastain ABC Kit, Vector) with
DAB as chromogen (modified from [65,67]. Sections were
examined under light microscopy.
Western Blot Analysis. After behavioral tests were
completed, animals were deeply anesthetized and decapitated
about 27–33 days following the 6-OHDA lesion. The brains were
removed, dissected and tissue samples were placed on dry ice.
Tissue samples were stored at minus 80uC until further processing.
Regions were homogenized in 40 mM Tris (pH 7.4), 150 mM
NaCl, 2 mM EDTA, 1 mM EGTA, 0.1% SDS, 1% TritonX100,
0.5 mM PMSF. The total protein concentration was determined
using a Bradford reagent (BioRad). 30 mg of homogenate isolated
from the indicated brain regions was heated at 95uC for 5 min,
resolved by 12% SDS-PAGE, transferred to nitrocellulose and
subjected to Western analysis.
Cell Culture. CAD mouse neuroblastoma cells [41,68] were
seeded into 6 well plates and grown in DMEM/F12 medium
supplemented with 10% fetal bovine serum and 1% Penicillin/
streptomycin. Eahy929 human endothelial cells were seeded into 6
well plates and grown in DMEM medium supplemented with 10%
serum, low glucose and hypoxanthine thymidine [69]. Cells were
lysed in 40 mM Tris (pH 7.4), 150 mM NaCl, 2 mM EDTA,
1m MN a 3VO4, 0.1% SDS, 1% TritonX100, 0.5 mM PMSF and
protease inhibitor (Sigma) end-over-end at 4uC for 1 hr. Lysates
were centrifuged at 1500xg for 5 min at 4uC and the supernatant
was collected. Protein concentration was determined using a
Bradford reagent (BioRad). Cell lysate was heated at 95uC for
5 min, resolved by 12% SDS-PAGE, transferred to nitrocellulose
and probed with the indicated antibodies.
SDS-PAGE and Immunoblotting. Protein samples were
separated on 12% SDS-PAGE and transferred from
polyacrylamide gels to nitrocellulose (0.45 mm) in 25 mM
TrisHCl, 192 mM glycine, 20% methanol and 0.2% SDS for
45 min at 15 V using a Semidry Blotting System (BioRad).
Membranes were blocked 4% not-fat dry milk in PBST (PBS,
0.1% (v/v) Tween20) for 30 min at room temperature and probed
with primary antibody for 2 hrs at room temperature or overnight
at 4uC. The membranes were washed in PBST and incubated with
horseradish peroxidase-coupled secondary antibody. The signal
was visualized with West Dura Pierce (Pierce Biotechnology, Inc.)
using the BioRad Chemi-DocH System (Biorad) and Hyperfilm
(Kodak). The quantification was carried out using QuantityOne
(BioRad).
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